Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes

European Heart Journal

Volumn 27, Issue 1, 2006, Pages 42-48

  Timmis, Adam D ^a   Chaitman, Bernard R ^b   Crager, Michael ^c  

^a LONDON CHEST HOSPITAL   (United Kingdom)

^b SAINT LOUIS UNIVERSITY   (United States)

^c CV THERAPEUTICS INC   (United States)

Author keywords

CARISA; Chronic stable angina; Diabetes; HbA1c; Ranolazine

Indexed keywords

AMLODIPINE; ATENOLOL; DILTIAZEM; GLYCERYL TRINITRATE; HEMOGLOBIN A1C; PLACEBO; RANOLAZINE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY MONITORING; EXERCISE TEST; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; METABOLIC SYNDROME X; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SCREENING TEST; STABLE ANGINA PECTORIS; TREADMILL EXERCISE;

AGED; ANGINA PECTORIS; CHRONIC DISEASE; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; EXERCISE TOLERANCE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; NITROGLYCERIN; PIPERAZINES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 28944448286     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi495     Document Type: Article

References (20)

1. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001;286:1195-1200.
2. Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med 2001;249:225-235.
3. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 1993;36:1175-1184.
4. International Diabetes Federation. Diabetes prevalence. http://www.idf.org/home/index.cfm?node=264 (2005).
5. Adult Treatment Panel III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002;106:3143-3421.
6. Kjaergaard SC, Hansen HH, Fog L, Bulow I, Christensen PD. In-hospital outcome for diabetic patients with acute myocardial infarction in the thrombolytic era. Scand Cardiovasc J 1999;33:166-170.
7. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291:309-316.
8. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, Pepine CJ, Wang W, Nelson JJ, Hebert DA, Wolff A; MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375-1382.
9. Cocco G, Rousseau MF, Bouvy T, Cheron P, Williams G, Detry JM, Pouleur H. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol 1992;20:131-138.
10. Repine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am J Cardiol 1999;84:46-50.
11. Liang K, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
12. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004;27(Suppl. 1):S15-S35.
13. Bartnik M, Malmberg K, Hamsten A, Efendic S, Norhammar A, Silveira A, Tenerz A, Ohrvik J, Ryden L. Abnormal glucose tolerance - a common risk factor in patients with acute myocardial infarction in comparison with population-based controls. J Intern Med 2004;256:288-297.
14. Bunn HF, Haney DN, Kamin S, Gabbay KH, Gallop PM. The biosynthesis of human hemoglobin A1c. Slow glycosylation of hemoglobin in vivo. J Clin Invest 1976;57:1652-1659.
15. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
16. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
17. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.
18. Derr R, Garrett E, Stacy GA, Saudek CD. Is HbA(1c) affected by glycemic instability? Diabetes Care 2003;26:2728-2733.
19. McIntosh A, Hutchinson A, Home PD, Brown F, Bruce A, Damerell A, Davis R, Field R, Frost G, Marshall S, Roddick J, Tesfaye S, Withers H, Suckling R, Smith S, Griffin S, Kaltenthaler E, Peters J, Feder G. Clinical Guidelines and Evidence Review for Type 2 Diabetes: Management of Blood Glucose. Sheffield: University of Sheffield; 2001.
20. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA 2001;286:1218-1227.